Nanobiotix SA of France has secured a development partnership for its lead product, a nanoparticle device that is intended to enhance the efficacy of radiotherapy, with PharmaEngine Inc of Taiwan. The upfront payment is $1 million. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
